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Summary In this study of papillary thyroid carcinomas, immunopositivity for EGF-receptor was present in a
majority of the cases (96%), although different staining patterns were observed. A distinct membraneous
reaction was found in 46%, whereas cytoplasmatic positivity of various degrees was present in 90% of the
cases. Strong cytoplasmic EGF-receptor staining was significantly associated with extra-thyroidal growth of
the primary tumour (P = 0.009), and it was furthermore related to decreased recurrence free survival
(P = 0.006). Membraneous EGF-receptor staining was not associated with recurrence free survival or patient
survival. Multivariate Cox analysis showed that lymph node metastases (P = 0.0009) and cytoplasmic EGF-
receptor staining (P = 0.0048) was independent indicators of tumour recurrences in this group of surgically
treated papillary thyroid carcinomas.
The prognosis of patients with papillary thyroid carcinoma
has previously been described in several reports (Byar et al.,
1979; Tubiana et al., 1985; Carcangiu et al., 1985; Akslen et
al., 1991), and the influence of sex, age and tumour stage has
been discussed. In addition, certain pathological features
such as marked nuclear atypia, necrosis or vascular invasion
are also important (Tennvall et al., 1985; Schindler et al.,
1991; Akslen et al., 1993). This information may improve the
risk estimation for individual patients.
In recent years, alterations in various growth factors and
their receptors have been established as important features of
the neoplastic process (Wynford-Thomas, 1991), among them
epidermal growth factor (EGF) and its receptor (EGF-R).
EGF is known to induce cell proliferation in several tissues,
and its effect is mediated via a tyrosine kinase type of recep-
tor (Carpenter & Cohen, 1979). It has previously been shown
by different methods that EGF-receptors are expressed in
papillary thyroid carcinomas (Duh et al., 1985; Lemoine et
al., 1991; Mizukami et al., 1991; Mizukami et al., 1992), but
the biological significance of this finding in terms of patient
prognosis is not known. The purpose of the present study
was therefore to perform a retrospective immunohisto-
chemical study of EGF-R expression in a series of papillary
thyroid carcinomas with special reference to its prognostic
importance.
Material and methods
Patients
This material has been described previously (Akslen et al.,
1993). Briefly, all 263 patients who were surgically treated for
thyroid cancer at the Department of Surgery, Haukeland
Hospital, University of Bergen in the period 1971-1985 have
been studied retrospectively. After histological revision and
subtyping of the carcinomas according to the WHO criteria
(Hedinger, 1988), 173 cases were found to be papillary car-
cinomas with a known primary tumour. One of the main
results from our previous study was that very few events
were observed in tumours with a diameter of 10 mm or
below (microcarcinomas according to the WHO criteria).
These were therefore excluded, thereby concentrating on
clinically significant papillary carcinomas. Sufficient material
was not available in two cases, leaving 125 tumours for
further analyses.
All patients were surgically treated in our institution, most
of them with total/near-total thyroidectomy (93%), and 91%
were considered to be radically treated, without macro-
scopically remaining tumour tissue. Pathologic lymph nodes
were removed mostly by using a 'node-picking' procedure.
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Variables
The following variables were studied: sex; age at diagnosis;
primary tumour extension (intra-thyroidal growth, tumour
growth in the thyroid gland capsule, major extra-thyroidal
extension); lymph node metastases (absent, intra-nodal
growth, extra-nodal growth) and EGF-receptor immunostain-
ing. Membraneous and cytoplasmatic staining were recorded
separately using a semiquantitative and subjective grading
system, considering both the intensity of staining and the
proportion of positive cells: Grade 1 = no staining, Grade
2 = weak or moderate positivity, Grade 3 = strong staining
in a high proportion of the tumour cells.
Immunohistochemistry
Immunohistochemical examination was performed on form-
alin-fixed and paraffin-embedded archival material using the
avidin-biotin complex method. Sections were incubated over-
night at 4°C with the primary antibody MU170-UC against
EGF-receptor (dilution 1:40) (Biogenex, CA). Antigen
localisation was achieved by the alkaline phosphatase anti-
alkaline phosphatase (APAAP) method. Negative controls
were incubated with PBS, and no positive staining was
observed.
Follow-up
Data concerning loco-regional tumour recurrences (local
lymph node metastases or soft tissue recurrences in the
thyroid bed), appearance of distant metastases, and patient
survival was achieved through examinations in our institution
or by correspondence to the patients' home physicians.
Recurrences or metastases within 4 months after the primary
operation were regarded as part of the primary status and
referred to the time of diagnosis. For all patients who died,
death certificates were examined as well as autopsy reports
when available. Last date of follow-up was July 1st, 1989,
and the median follow-up time was 7.3 years (maximum 18.3
years). No patient was lost to follow-up.
Statistics
Analyses were performed by various programmes in the
statistical package BMDP (Dixon, 1985). Associations
between different variables were assessed by Pearson's
chi-square test. Survival analysis (life-table method) was done
by BMDP-1L using the Mantel-Cox test for differences
between groups, and plots for cumulative proportion surviv-
ing are given. Recurrence free survival, i.e. the time from
diagnosis until the appearance of loco-regional recurrences
or distant spread, and the patient survival (survival time until
thyroid cancer deaths) were studied. Deaths from intercur-
rent disease, without tumour recurrence, were censored in the
analysis of recurrence-free survival. The influence of co-
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variates on survival was analysed by the proportional
hazards method (Cox & Oakes, 1984) with BMDP-2L, using
a forward stepwise procedure. In these analyses, all variables
with a P-value of 0.10 or less in the life-table studies were
included. Estimated regression coefficients and P-values are
given in the Tables.
Results
Table I shows the distribution of the cases according to
major clinicopathologic variables. Definite extra-thyroidal
invasion was present in 19% of the cases, and 45% had
lymph node metastases at the time of diagnosis.
Tumour recurrences during the follow-up period occurred
in 27 patients (22%). Of the 25 deaths, 14 were due to
thyroid cancer (56%).
EGF-receptor immunostaining was found in 120 of 125
cases (96%), whereas five cases were completely negative. In
some cases, a weak positivity was found in follicular cells in
adjacent non-neoplastic thyroid tissue. Table II shows that a
distinct membraneous EGF-receptor staining (grade 2 and 3)
was present in 46% of the cases, and the staining was
especially evident on the apical surface of the tumour cells
(Figure 1). In 90% of the tumours, a cytoplasmic pattern of
positive staining was found (Figure 1). This was a diffuse or
finely granular staining in most cases, but in some tumours
coarse granules were present in the supranuclear part of the
cytoplasm. Of the cases with cytoplasmatic positivity, 12%
showed a marked (grade 3) staining reaction. Mixed staining
patterns were also observed (Figure 1).
Table III shows that the degree of cytoplasmic immuno-
positivity was significantly associated with the extent of
primary tumour infiltration (P=0.009). The frequency of
cases with tumour growth in the thyroid capsule or extra-
thyroidal invasion was 17%, 63% and 71% in grade 1, 2 and
3 tumours, respectively. Membraneous staining was not
associated with any of the variables.
Univariate analysis of recurrence free survival (life-table
method) showed that primary tumour extent and lymph node
metastases were significant variables (Table IV). Cytoplasmic
EGF-receptor staining was also found to be significant,
P = 0.006 using the Mantel Cox' trend test (Table IV, Figure
2). Grade 3 cytoplasmic staining was significantly different
from Grade 2 positivity (P = 0.05). Patient survival was
associated with sex, age and primary tumour extension, but
EGF-receptor staining was not significant (Table IV).
Multivariate survival analysis (Cox' method) of recurrence
free survival including sex, age, primary tumour extent,
lymph node metastases and cytoplasmic EGF-receptor
immunostaining showed that only lymph node metastases
(P = 0.0009) and EGF-receptor positivity (P = 0.0048) re-
mained as significant and independent variables (Table V).
EGF-receptor was found to be the strongest prognostic fac-
tor, with a regression coefficient of 1.28, compared to 0.81
for lymph node metastases. Multivariate analysis (Cox'
Table I Distribution of patients with papillary thyroid carcinoma
according to important clinicopathologic variables (n = 125)
Variable n %
Sex
males 36 28.8
females 89 71.2
Age
0-49 years 71 56.8
50 + years 54 43.2
Primary tumour extent
intra-thyroidal tumour 51 40.8
thyroid capsular invasion 50 40.0
extra-thyroidal invasion 24 19.2
Lymph node metastases
absent 67 54.5
intra-nodal growth 20 16.3
extra-nodal growth 36 29.2
method) of patient survival was not performed since EGF-
receptor immunostaining turned out to be not significant in
the univariate life-table study.
Discussion
The present study of papillary thyroid carcinoma indicates
that EGF-receptors are present in a majority of the cases.
Corresponding results have been reported by others using
biochemical (Duh et al., 1985; Makinen et al., 1988; Masuda
et al., 1988; Di Carlo et al., 1990) or immunohistochemical
methods (Lemoine et al., 1991; Song et al., 1991; Mizukami
et al., 1992). Our results add further evidence to the role of
oncogenes in development and progression of thyroid
tumours. In a recent study, the presence of transforming
growth factor ox (TGF-a), a known EGF-R ligand, as well as
TGF-a mRNA was found in the epithelial component of
papillary carcinomas, indicating an autocrine growth factor
production (Haugen et al., in press). In addition to altera-
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Figure 1 Patterns of EGF-receptor immunostaining in papillary
thyroid carcinomas. a, membraneous staining, x 428; b, mixed
membraneous and cytoplasmic staining, x 428; c, strong (grade
3) cytoplasmic staining, x 428.810 L.A. AKSLEN et al.
tions in the EGF-R system, we have previously shown that
c-erbB-2 expression is also increased (Haugen et al., 1992).
The pattern and intensity of EGF-receptor immunostain-
ing varied considerably between different tumours. Increased
expression in the tumour cell cytoplasm was significantly
associated wtih extra-thyroidal growth of the primary
tumours. However, no relationship to co-existing lymph node
metastases was found, in line with studies on breast cancer
(Bolla et al., 1992). Previous reports on carcinomas of the
urinary bladder, stomach and large bowel have also sug-
gested an association between EGF-R positivity and invasive
growth (Neal et al., 1985; Yasui et al., 1988; Smith et al.,
1989; Yonemura et al., 1991), but the mechanism is not clear.
Some in vitro studies indicate that EGF may stimulate the
Table II Patterns and intensity of EGF-receptor immunostaining in
papillary thyroid carcinoma (n = 125)
Membraneous Cytoplasmic
staining staining
Staininga n % n %
Grade 1 67 53.6 12 9.6
Grade 2 46 36.8 99 79.2
Grade 3 12 9.6 14 11.2
aGrade 1 = nostaining; Grade 2 = slight ormoderatestaining; Grade
3 = marked staining.
Table III Associations between pattern of EGF-receptor immuno-
staining and important clinicopathologic variables in patients with
papillary thyroid carcinoma (n = 125)
P-value"
Membraneous Cytoplasmic
Variables staining" stainingb
Sex 0.9 0.8
Agec 0.11 0.9
Primary tumour extentd 0.2 O.009e
Lymph node metastasesf 0.5 0.4
aPearson's chi-square. bGrades 1, 2, 3 (see Material and methods).
C0-49 years, 50 + years. dintra-thyroidal, thyroid capsular invasion,
extra-thyroidal invasion. eFor details, see Results. fabsent, intra-nodal
growth, extra-nodal growth.
secretion of proteolytic enzymes (Lee & Weinstein, 1978;
Boyd, 1989), but in a study of EGF-R and cathepsin D in
endometrial and cervical tumours, no significant relationship
was found (Scambia et al., 1991). In addition, cellular migra-
tion may be stimulated by EGF (Westermark et al., 1982).
Positivity for EGF-receptor was significantly related to
increased risk of recurrent disease in papillary thyroid car-
cinomas, in contrast to a recent study where no prognostic
importance could be found (Mizukami et al., 1992). Our
present results are thus in general agreement with reports on
breast cancer, where the presence of EGF-receptors has been
documented to be an important predictor of tumour recur-
rences as well as patient survival (Sainsbury et al., 1987;
Grimaux et al., 1989; Nicholson et al., 1991; Toi et al., 1991).
Further studies using quantitative methods should now be
performed.
The mechanism of EGF-receptor influence on patient
prognosis has not yet been clarified. In breast cancer, in-
creased expression of EGF-R has been related to dediffer-
entiation of tumour cells, with increased cellular atypia,
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Figure 2 Recurrence-free survival according to cytoplasmic
EGF-receptor immunostaining in papillary thyroid carcinomas.
Table IV Univariate survival analysis(life-tablemethod) ofpatientswith papillarythyroidcarcinomaaccording
to clinicopathologic variables and EGF-receptor immunostaining, n = 125 (the figures in parenthesis give the
number of patients who were alive after 10 years and eligible for estimation of 10-year survival; the P-values
correspond with a standard life-table analysis, based on all patients and observed events during the whole
follow-up period)
10-year recurrence 10-year patient
Variables n free survival (%)a pb survival (%) pb
Sex 0.2 0.014
females 89 (28) 76.5 91.6
males 36 (10) 66.0 81.6
Age 0.05 <0.00005
0-49 years 71 (25) 81.4 98.2
50+ years 54 (13) 61.7 75.8
Primary tumour extent 0.0001 0.010
intra-thyroidal 51 (22) 95.5 98.0
thyroid capsule invasion 50 (12) 50.3 81.7
extra-thyroidal invasion 24 (4) 65.3 80.9
Lymph node metastases <0.00005 0.3
absent 67 (22) 88.8 93.3
intra-nodal growth 20 (6) 82.2 79.8
extra-nodal growth 36 (9) 33.3 84.0
EGF-receptor immunostainingc
membraneous staining 0.7 0.3
grade 1 67 (16) 73.9 83.5
grade 2 46 (17) 76.6 92.8
grade 3 12 (5) 63.5 100.0
cytoplasmic staining 0.006 0.11
grade 1 12 (7) 100.0 100.0
grade 2 99 (25) 73.5 85.5
grade 3 14 (6) 47.0 100.0
aOf 125 cases included, nine were not radically treated and excluded in the analysesofrecurrence free survival.
bMantel-Cox' test. 'Trend version of the Mantel-Cox' test.EGF-RECEPTOR IN PAPILLARY THYROID CARCINOMA 811
Table V Multivariate analysis of recurrence free survival (Cox'
proportional hazards method) of patients with papillary thyroid
carcinoma (n = 11 3)a
Regression Standard
Variables coefficient error P-valueb
Lymph node metastasesc 0.81 0.26 0.0009
EGF-receptor" 1.28 0.43 0.0048
(cytoplasmic staining)
aof 125 cases, nine were not radically treated and were therefore
excluded, and three cases were excluded due to lack ofinformation. bL
ratio test of significance. Ccategories: absent, intra-nodal growth,
extra-nodal growth. dCategories: grade 1, grade 2, grade 3.
reduced concentration of oestrogen receptors and a higher
proliferative fraction as measured by Ki-67 immunopositivity
(Fitzpatrick et al., 1984; Bolla et al., 1992). An inverse cor-
relation between EGF-R content and TSH-response has also
been noted in anaplastic thyroid carcinomas (Di Carlo et al.,
1990). These findings indicate that increased EGF-R expres-
sion is associated with proliferative activity in tumour cells
and reduced dependency of normal growth regulators.
Interestingly, two specific staining patterns were observed
in the present study. A distinct membraneous positivity was
found in 46% of the cases, whereas a diffuse or granular
cytoplasmic staining was observed in 90% of all tumours.
These patterns have been briefly noted by others (Kashima et
al., 1991; Mizukami et al., 1992). Only the cytoplasmatic
form of staining, however, showed a significant association
with patient prognosis. Earlier studies (Lemoine et al., 1990;
Aasland et al., 1988; Aasland et al., 1990) indicate that
increased expression of EGF-R in thyroid tumours is not due
to gene amplification or gross rearrangements. Therefore,
epigenetic changes may be involved, and recent Western blot
studies of fresh material indicate that modified proteins are
present in some cases (Haugen et al., in preparation).
In conclusion, the present study using semiquantitative
immunohistochemical assessment indicates that expression of
EGF-receptors may be an important feature of papillary
thyroid carcinomas, and various staining patterns seem to be
of different biological significance. Strong cytoplasmatic
immunopositivity was associated with extra-thyroidal tumour
invasion and found by multivariate analysis to be the
strongest independent predictor of recurrent disease. How-
ever, quantitative methods should be used in further studies
to establish this association.
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